Spesolimab, marketed under the brand name Spevigo, received FDA approval for the treatment of generalized pustular psoriasis flares in adults.

Auvelity, under its generic name bupropion and dextromethorphan, has been approved by the FDA for the treatment of major depressive disorder.

Venlafaxine received FDA approval for the treatment of major depressive disorder on December 28, 1993.

Vutrisiran received FDA approval on June 13, 2022, under the brand name Amvuttra.

Amoxicillin and vonoprazan, marketed under the brand name Voquezna Dual Pak, is a combination medication approved by the FDA.

Mavacamten received its first approval on 28 April 2022 in the USA for the treatment of adults with symptomatic New York Heart Association (NYHA).

Oteseconazole, with the generic name oteseconazole and marketed under the brand name Vivjoa, is an oral capsule formulation primarily used as an azole antifungal medication.

Pluvicto, whose generic name is lutetium Lu 177 vipivotide tetraxetan, received FDA approval for its indicated use in adult patients with PSMA-positive mCRPC.

Nivolumab and relatlimab received FDA approval for the treatment of unresectable or metastatic melanoma on March 18, 2022.

Ganaxolone, marketed under the brand name Ztalmy, is FDA approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in individuals aged 2 years and older.

Pacritinib, with the generic name pacritinib [pak-RI-ti-nib], is approved by the FDA for the treatment of myelofibrosis in adults.

Ciltacabtagene autoleucel received FDA approval on February 28, 2022.